DeSimone Jill 4

What Happened
Jill DeSimone, a director of Praxis Precision Medicines (PRAX), exercised a total of 11,600 option shares on June 24, 2026 (8,566 shares at $44.25 and 3,034 shares at $147.30; total exercise cost $825,954) and sold those 11,600 shares in multiple open‑market transactions the same day for aggregate proceeds of $3,611,334 (weighted‑average sale price ≈ $311.32). Net cash proceeds from the exercise-and-sale were roughly $2.79M. The options cited were fully vested as of May 23, 2025 and June 5, 2025.

Key Details

• Transaction date: June 24, 2026; Form 4 filed June 26, 2026 (timely filing).
• Exercise details: 8,566 shares @ $44.25 ($379,046) and 3,034 shares @ $147.30 ($446,908).
• Sales: 11,600 shares sold across multiple trades for $3,611,334 (per‑lot weighted average prices/ranges noted in filing footnotes; overall avg ≈ $311.32).
• Footnotes: Sales were effected pursuant to a Rule 10b5‑1 trading plan adopted March 25, 2026 (F1). Several footnotes (F2–F12) provide per‑trade price ranges; F13 and F14 note the options were fully vested prior to exercise.
• Shares owned after the reported transactions: not specified in the provided excerpt of the filing.
• Transaction codes: M = exercise/conversion of derivative; S = open market sale.

Context
This was an exercise of vested options followed by same‑day open‑market sales (commonly referred to as a cashless exercise or exercise-and-sell). Sales under a pre‑arranged 10b5‑1 plan are routine and do not, by themselves, indicate the director’s current view of the company. The reporting person is a company director (not a 10% owner), and the filing does not present any late‑filing issues based on the dates shown.